The Molecular Testing for Respiratory Pathogens segmentation by type categorizes the market into PCR‑based assays, isothermal amplification platforms, next‑generation sequencing (NGS) solutions, and hybrid‑capture technologies. PCR‑based assays remain the dominant share, representing approximately 60 % of sales, due to their established workflow, high sensitivity, and compatibility with existing laboratory automation. Isothermal amplification, accounting for roughly 20 %, offers faster turnaround and reduced instrument complexity, appealing to point‑of‑care settings and low‑resource environments. NGS solutions, contributing about 15 %, enable comprehensive pathogen panels, strain typing, and antimicrobial‑resistance detection, thereby serving research institutions and advanced clinical laboratories seeking high‑resolution data. Hybrid‑capture methods, with an estimated 5 % share, combine targeted enrichment with sequencing to improve detection limits for low‑titer specimens. Each type imposes distinct cost‑of‑ownership, throughput, and regulatory pathways, which collectively define the market’s total addressable volume. Recognizing this type taxonomy assists stakeholders in allocating R&D resources, forecasting technology adoption curves, and aligning product portfolios with the evolving diagnostic landscape.
